论文部分内容阅读
目的探讨胰激肽原酶肠溶片联合腺苷钴胺治疗糖尿病周围神经病变的临床疗效。方法选取沈阳二四五医院2015年4月—2016年3月收治的糖尿病周围神经病变患者92例,随机将患者分成治疗组与对照组,各46例。两组患者均予以常规饮食控制、适当活动和降糖药物治疗,对照组在此基础上予以胰激肽原酶肠溶片治疗,治疗组在对照组基础上予以腺苷钴胺片治疗,两组患者均持续治疗4周。比较两组患者治疗前后肌电图指标、神经病变自觉症状问卷量表(TSS)评分、多伦多临床神经病变量表(TCSS)评分、视觉模拟评分法(VAS)评分、不良反应发生情况。结果治疗前两组患者腓总神经、正中神经的感觉神经传导速度与运动神经传导速度比较,差异无统计学意义(P>0.05);治疗后治疗组患者腓总神经、正中神经的感觉神经传导速度与运动神经传导速度高于对照组(P<0.05)。治疗前两组患者TCSS评分、TSS评分和VAS评分比较,差异无统计学意义(P>0.05);治疗后治疗组TCSS评分、TSS评分和VAS评分低于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论胰激肽原酶肠溶片联合腺苷钴胺治疗糖尿病周围神经病变的临床疗效确切,可明显改善患者神经病变程度,且安全性高。
Objective To investigate the clinical efficacy of pancreatic kallikrein enteric-coated tablets combined with adenosylcobalamin in the treatment of diabetic peripheral neuropathy. Methods Ninety-two patients with diabetic peripheral neuropathy admitted from April 2015 to March 2016 in Shenyang 245 Hospital were randomly divided into treatment group and control group, with 46 cases in each group. The two groups of patients were given routine diet control, appropriate activities and hypoglycemic drugs treatment, the control group was treated with pancreatic kallikrein enteric-coated tablets, the treatment group was given adenosine cobalamin tablets on the basis of the control group, two Group patients were treated for 4 weeks. Electroencephalogram, neurological symptoms questionnaire (TSS), Toronto clinical neurological disease scale (TCSS) score, visual analog scale (VAS) score and adverse reactions were compared between the two groups before and after treatment. Results There was no significant difference in sensory nerve conduction velocity and motor nerve conduction velocity of the common peroneal nerve and median nerve between the two groups before treatment (P> 0.05). After treatment, the sensory nerve conduction of the common and median nerve The velocity and motor nerve conduction velocity were higher than the control group (P <0.05). There was no significant difference in TCSS score, TSS score and VAS score between the two groups before treatment (P> 0.05). After treatment, TCSS score, TSS score and VAS score of the treatment group were lower than those of the control group (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion The combination of pancreatic kallikrein enteric-coated tablets and adenosylcobalamin in the treatment of diabetic peripheral neuropathy has definite clinical curative effect, which can significantly improve the degree of neuropathy in patients with high safety.